MIAMI, FL June 19, 2020
– ArisGlobal,the leading provider of life sciences software that automates drug development functions for over 300 life sciences companies, today announced that Dr. Rob Scott
has been appointed to the company’s Board of Directors. Dr. Scott joins the board with over 30 years of experience in the life sciences industry, most recently serving as the Chief Medical Officer and Head of Development at AbbVie, where he led a team of more than 4,000 individuals across 52 countries. Dr Scott is considered an industry leader in the use of predictive analytics and big data to design and implement clinical trials, and in digital transformation of clinical research, and will bring invaluable perspective to the future development of ArisGlobal’s LifeSphere platform.
“I am very excited to be joining the ArisGlobal team,” Dr. Scott said. “Their deep expertise and long-term perspective have generated a next generation suite of products that focuses on automation to lower the cost and improve the quality of clinical research. This matches my own journey to make clinical development more efficient to help patients who still need new therapeutic options.”
“We are honored to have Dr. Scott join our Board of Directors,” said Sankesh Abbhi, President and CEO of ArisGlobal. “We know that his extensive life sciences experience, in addition to his keen understanding of digital transformation within clinical research, will provide ArisGlobal with crucial insight into the evolving needs of our customers.”
About Dr. Rob Scott
Dr. Rob Scott has held leadership positions for over 30 years in the world’s leading biopharma companies, including J&J, Pfizer, Amgen and AbbVie. During that time, he has led development teams responsible for highly successful brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Prior to his recent retirement as Chief Medical Officer and Head of Development for AbbVie, Dr. Scott was responsible for a team of over 4,000 individuals across 52 countries, a budget of nearly US$3 billion and programs involving more than 40 new molecular entities.
Prior to joining AbbVie, Dr. Scott served as Vice President of Global Development for Amgen from 2010 and 2016, where he conducted the first outcome study for a PCSK9i, FOURIER. From 2002 until 2007, he was the Chief Medical Officer and Executive Vice President of Research and Development at AtheroGenics. While there he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech.
Dr. Scott also worked for Pfizer, one of the world’s premier biopharmaceutical companies, from 1992 to 2002. While there, he was intimately involved in many cardiovascular clinical trials. He also was integral in developing the cholesterol drug Lipitor and Norvasc, a drug used to treat high blood pressure.
Dr. Scott has served on many committees and boards, including as a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 until 2016, the board of Transcelerate, and as a member of the PhRMA Research and Development Leadership Forum.
For more information on ArisGlobal, please visit our website: